Abstract
BACKGROUND AND AIMS: T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) is mainly expressed by immune cells and plays an immunomodulatory role in cardiovascular disease. However, the prognostic value of Tim-3 in acute decompensated heart failure (ADHF) is unclear. This study aimed to investigate the expression profile of Tim-3 on CD4(+) and CD8(+) T cells in patients with ADHF and its impact on their prognosis. METHODS: In this prospective study, 84 patients who were hospitalized with ADHF and 83 patients without heart failure were enrolled. Main clinical data were collected during patient visits. The Tim-3 expression on CD4(+) and CD8(+) T cells in peripheral blood samples was assayed by flow cytometry. Long-term prognosis of the patients with ADHF was evaluated by major adverse cardiac and cerebrovascular events (MACCE) over a 12-month follow-up period. RESULTS: We found that the Tim-3 expression on CD4(+) T cells [2.08% (1.15-2.67%) vs. 0.88% (0.56-1.39%), p < 0.001] and CD8(+) T cells [3.81% (2.24-6.03%) vs. 1.36% (0.76-3.00%), p < 0.001] in ADHF group were significantly increased vs. the non-ADHF group. Logistic analysis revealed that high levels of Tim-3 expressed on CD4(+) and CD8(+) T cells were independent risk factors of ADHF (OR: 2.76; 95% CI: 1.34-5.65, p = 0.006; OR: 2.58; 95% CI: 1.26-5.31, p = 0.010, respectively). ROC curve analysis showed that the high level of Tim-3 on CD4(+) or CD8(+) T cells as a biomarker has predictive performance for ADHF (AUC: 0.75; 95% CI: 0.68-0.83; AUC: 0.78, 95% CI: 0.71-0.85, respectively). During a median follow-up of 12 months, the Cox regression analysis revealed that higher Tim-3 on CD4(+) and CD8(+) T cells were strongly associated with increased risks of MACCE within 12 months after ADHF (HR: 2.613; 95% CI: 1.11-6.13, p = 0.027; HR: 2.762, 95% CI: 1.15-6.63, p = 0.023; respectively). CONCLUSION: Our research indicated that the expression level of Tim-3 on CD4(+) and CD8(+) T cells, elevated in patients with ADHF, was an independent predictor of MACCE within 12 months after ADHF. It suggests a potential immunoregulatory role of Tim-3 signaling system in the mechanism of ADHF.